Pro members get same-minute coverage on the stocks they track. Free plans update twice a day.
Get ProCounts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
Dr Reddy’s reports muted Q1FY27 results, net profit drops 69%
Direct news · High influence · Short term
Dr. Reddy's Q1 PAT Plunges 69%; US Generics Pricing Weighs Heavy
Direct news · High influence · Long term
Nifty Pharma Index Falls Nearly 2% on Trump Tariff Plan for Generic Drugs
Direct news · Medium influence · Long term
Dr Reddy's Stock: Company Halts Semaglutide API Over Impurity Issue
Direct news · Medium influence · Short term
Dr Reddy's Stock: Company Targets 6 to 7 Million Semaglutide Pens in FY27
Direct news · Medium influence · Long term
Macro, commodity, FX and regulatory forces that moved DRREDDY in this range, with the stories behind each.
Sign up free to track DRREDDY, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track DRREDDY for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Nifty Pharma Index Falls Nearly 2% on Trump Tariff Plan for Generic Drugs
How news sentiment on Dr. Reddy's Laboratories Ltd. (DRREDDY) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
